Compare ACADIA Pharmaceuticals Inc. (ACAD) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs BlackRock TCP Capital Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while BlackRock TCP Capital Corp trades at $3.19 (market cap $268.49M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 16.7× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.25% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TCPC | |
|---|---|---|
Market Cap | $4.49B | $268.49M |
Sector | Health | Financials |
52-Week High | $28.06 | $7.90 |
52-Week Low | $20.06 | $3.14 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 26.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TCPC trades at $3.25, down 3.27% on the day, with a bearish technical outlook and negative revenue trends. The stock shows a low price-to-book ratio of 0.48 but faces challenges with negative net income and declining profitability. Recent news highlights a shareholder investigation into fiduciary duties, adding to investor concerns amid mixed analyst sentiment.
The outlook remains cautious due to persistent losses and legal scrutiny. Opportunities exist from the discounted book value and dividend yield, but risks from earnings misses and negative cash flow outweigh near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
